News
Sale History: 2021 KEENOV, $62,000; 2022 KEESEP, $150,000; 2023 OBSMAR, $305,000 .
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...
There aren't many large plots left in Scott's Addition to build upon. Plus the cost of construction and financing has surged.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback